Back to discover
Disease

Lyme Disease

Late-stage therapeutic developmentEmerging research
MeSHLyme Disease
3
Publications
14
Clinical trials
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 5 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
Clinical Milestones8View
Results expected 5
Recently completed 2
Other updates 1
Activity timeline8

Clinical trials

10 sponsors · 4 new · 2 completed in the last 12 months (net +3)

The current development programme across all trial phases.

Clinical programme
14
All trials
5
Active
7
Late-stage
6
Completed
Late-stage studies

A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A FIFTH DOSE OF 6-VALENT OSPA-BASED LYME DISEASE VACCINE, VLA15, IN HEALTHY PARTICIPANTS ≥7 YEARS OF AGE

Phase 3 · Recruiting · Pfizer

Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in the Context of Erythema Migrans (Early Skin Form of Lyme Borreliosis))

Phase 4 · Recruiting · Biocodex

Persistent Lyme Empiric Antibiotic Study Europe. A Prospective, Randomised Study Comparing Two Prolonged Oral Antibiotic Strategies After Initial Intravenous Ceftriaxone Therapy for Patients With Symptoms of Proven or Possible Persistent Lyme Disease

Phase 4 · Completed · Radboud University Medical Center

Study and Treatment of Post Lyme Disease (STOP-LD)

Phase 3 · Completed · National Institute of Allergy and Infectious Diseases (NIAID)

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease

Phase 3 · Completed · National Institute of Allergy and Infectious Diseases (NIAID)

A PHASE 3, MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY, AND LOT CONSISTENCY OF A 6-VALENT OSPA-BASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS ≥5 YEARS OF AGE

Phase 3 · Completed · Pfizer
Recruiting

A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A FIFTH DOSE OF 6-VALENT OSPA-BASED LYME DISEASE VACCINE, VLA15, IN HEALTHY PARTICIPANTS ≥7 YEARS OF AGE

Phase 3 · Recruiting · Pfizer

Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in the Context of Erythema Migrans (Early Skin Form of Lyme Borreliosis))

Phase 4 · Recruiting · Biocodex

Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial of Pulse Dosed Ceftriaxone for Post-Treatment Lyme Disease

Early Phase 1 · Recruiting · State University of New York - Upstate Medical University

A Phase 2, Randomized, Observer-blind, Dose-finding, Placebo-controlled Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982, an mRNA Vaccine to Prevent Lyme Disease in Healthy Adult Participants (18 to 70 Years of Age)

Phase 2 · Recruiting · ModernaTX, Inc.
Recently completed

T4 - Tetracycline Treatment Tolerability Trial A Pilot Study Examining the Feasibility and Tolerability of Tetracycline Therapy in Post-Treatment Lyme Disease (PTLD)

Phase 2 · Completed · Johns Hopkins University

A PHASE 3, MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY, AND LOT CONSISTENCY OF A 6-VALENT OSPA-BASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS ≥5 YEARS OF AGE

Phase 3 · Completed · Pfizer

Effects of Psilocybin in Post-Treatment Lyme Disease

Phase 1 · Completed · Johns Hopkins University

Persistent Lyme Empiric Antibiotic Study Europe. A Prospective, Randomised Study Comparing Two Prolonged Oral Antibiotic Strategies After Initial Intravenous Ceftriaxone Therapy for Patients With Symptoms of Proven or Possible Persistent Lyme Disease

Phase 4 · Completed · Radboud University Medical Center

Study and Treatment of Post Lyme Disease (STOP-LD)

Phase 3 · Completed · National Institute of Allergy and Infectious Diseases (NIAID)

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease

Phase 3 · Completed · National Institute of Allergy and Infectious Diseases (NIAID)

Research activity

3 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20232024
Major themes5
  • Lyme Disease3
  • Anaplasma phagocytophilum1
  • Borrelia burgdorferi1
  • Ixodes1
  • Tick-Borne Diseases1
Leading journals3
  • JMIR public health and surveillance1
  • PloS one1
  • Zoonoses and public health1
Leading researchers8
  • Bourgeois AC1
  • Brooks C1
  • Cho S1
  • Clow KM1
  • Crandall KE1
  • Evans GA1
  • Gasmi S1
  • Hatchette TF1
Affiliations (unnormalised)6
  • Department of Pathology and Laboratory Medicine1
  • Kingston Health Sciences Centre1
  • Laboratory for Human Neurobiology1
  • McGill University1
  • Schar School of Policy and Government1
  • School of Economic1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

An infectious disease caused by a spirochete, BORRELIA BURGDORFERI, which is transmitted chiefly by Ixodes dammini (see IXODES) and pacificus ticks in the United States and Ixodes ricinis (see IXODES) in Europe. It is a disease with early and late cutaneous manifestations plus involvement of the nervous system, heart, eye, and joints in variable combinations. The disease was formerly known as Lyme arthritis and first discovered at Old Lyme, Connecticut.

Identifiers
MeSHLyme Disease
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.